Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2025-05-21 00:00:00 ET · period of report 2025-05-19 · accession 0001415889-25-013944 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-21 | 2025-05-19 | KNSA | Tessari Eben | COO | S - Sale+OE | $26.41 | -12.0K | 72.4K | -14% | -$316.9K |
| D | 2025-05-21 | 2025-05-19 | KNSA | Tessari Eben | COO | M - OptEx | $3.80 | +7,000 | 84.4K | +9% | +$26.6K |
| D | 2025-05-21 | 2025-05-19 | KNSA | Tessari Eben | COO | M - OptEx | $0.00 | -7,000 | 49 | -99% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Share | 2025-05-19 | S | D | 12,000 | $26.41 | 72,363 | D | — | — | (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $25.975 and $26.76. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
| 2 | Common | Class A Ordinary Share | 2025-05-19 | M | A | 7,000 | $3.80 | 84,363 | D | — | — | |
| 3 | Derivative | Share Option | 2025-05-19 | M | D | 7,000 | $0.00 | 49 | D | $3.80 · — to 2027-06-28 | 7,000 Class A Ordinary Share | (F3) The option is fully vested and exercisable. |